Myeloma Patients May Safely Discontinue Maintenance Therapy After Two Years

A recent clinical trial suggests that individuals with newly diagnosed multiple myeloma, who have not undergone an autologous stem cell transplant, can cease lenalidomide maintenance therapy after two years without negatively impacting their survival rates. This discovery could lead to changes in current clinical practices for managing myeloma, potentially reducing long-term treatment burden.